Nicholas A. Saccomano - 22 Dec 2025 Form 4 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Role
President and CEO, Director
Signature
/s/ Jason Leverone, by power of attorney
Issuer symbol
OKUR
Transactions as of
22 Dec 2025
Net transactions value
-$258
Form type
4
Filing time
23 Dec 2025, 20:09:47 UTC
Previous filing
24 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Saccomano Nicholas A President and CEO, Director C/O ONKURE THERAPEUTICS, INC., 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER /s/ Jason Leverone, by power of attorney 23 Dec 2025 0001609284

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OKUR Class A Common Stock Sale $258 -87 -1.2% $2.97 7,419 22 Dec 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
F2 This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F4 Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025.